Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease

C

Chinese PLA General Hospital (301 Hospital)

Status

Enrolling

Conditions

Microbiome
Immune Function
Anti-MDA5 Antibody Positive Dermatomyositis

Study type

Observational

Funder types

Other

Identifiers

NCT06203249
Microecology and Immunity 1

Details and patient eligibility

About

The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody positive dermatomyositis.

Full description

Methods: Bronchoalveolar lavage specimens of patients with anti-MDA5 antibody positive dermatomyositis and interstitial lung disease were collected and studied to analyze the relationship between the composition of patients' microecology and the occurrence and development of disease.

Enrollment

50 estimated patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who meet the diagnostic criteria of dermatomyositis and anti-MDA 5 antibody positive.
  • Anti-MDA5 antibody positive DM patients with RPILD meet the diagnostic criteria for RPILD.
  • Must have undergone bronchoalveolar lavage.
  • Age≥18 years old.
  • Patients who signed informed consent forms

Exclusion criteria

  • Patients who had other connective tissue diseases.
  • Patients with ILD or RPILD caused by infection, tumors, drugs, biochemistry and other factors.
  • Pregnant or lactating patients.
  • The patient also participated in any other clinical trial.
  • Disagreement for inclusion in this study

Trial contacts and locations

1

Loading...

Central trial contact

Zhimei Duan, doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems